investors.liminalbiosciences.com Open in urlscan Pro
2606:4700::6811:ca9f  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Menu
Menu
 * Home
 * About Us
 * Product Pipeline
 * Investors & Media
 * Careers
 * Subscribe



About Us
 * Our Company
 * Our Values
 * Our Strategy
 * Meet the Management Team
 * Our Board Members



Product Pipeline
 * Selective GPR84 Antagonist
 * Selective OXER1 Antagonist



Investors & Media
 * Investor Resources
 * Press Releases
 * Financial Reports
 * Webcasts
 * SEC Filings
 * SEDAR® Filings
 * Stock Information
 * Corporate Governance
 * Investor Briefcase
 * Frequently Asked Questions



Careers
 * Career Opportunities
 * Resume Submission

Subscribe to our newsletter

Contact Us
 * Home
 * About Us
   * Our Company
   * Our Values
   * Our Strategy
   * Meet the Management Team
   * Our Board Members
 * Product Pipeline
   * Selective GPR84 Antagonist
   * Selective OXER1 Antagonist

 * Investors & Media
 * Careers
 * Subscribe


Investors Home Click here to open the mobile navigation dropdown
 * Investors Home
 * News & Events
   
    * Press Releases
    * Events

 * Financial Reports
   
    * SEC Filings
    * SEDAR® Filings

 * Stock Information
   
    * Interactive Chart

 * Corporate Governance
   
    * Corporate Governance
    * Management Team
    * Board of Directors
    * Board Committees

 * Shareholder Information
 * Resources
   
    * Frequently Asked Questions
    * Email Alerts
    * Contact Us

Investor Resources

Who We Are

Liminal BioSciences is a development-stage biopharmaceutical company focused on
developing distinctive novel small molecule therapeutics for inflammatory,
fibrotic and metabolic diseases using our drug discovery platform with a
data-driven approach. Liminal BioSciences has its registered office in
Bellevlle, Ontario and talent hubs in Laval, Quebec, Canada, and Cambridge, UK.

Our common shares are listed for trading on the Nasdaq Market (LMNL).

Stock Quote
NASDAQLMNL
$0.47
Last Price
$0.01
(3.24%)
Change
16.6K
Volume
$14.7M
Market Cap
Currency in USD.
Quote data delayed by at least 15 minutes.
OUR DEVELOPMENT PROGRAMS

GPR84 Antagonist

The GPR84 receptor is primarily expressed in immune cells in addition to
multiple organ systems. It plays a key role in the linkage and regulation of the
inflammatory and metabolic response, and promotes fibrosis. Learn more.

--------------------------------------------------------------------------------

OXER1 Antagonist 

OXER1 is a GPCR receptor which is mainly expressed ininflammatory cells. OXER1
is highly selective for 5 oxo ETE, one of the most powerful chemo attractants
and activators of eosinophils. Learn more.

Recent News
Email Alerts
Nov 9, 2022
Liminal BioSciences Reports Third Quarter 2022 Financial Results and Business
Highlights

$40.8M of cash and cash equivalents at September 30, 2022 Discontinuation of
fezagepras development Termination of legacy CDMO agreement for cash savings of
$33.1 million Net loss from continuing...

Nov 8, 2022
Liminal BioSciences to Report Third Quarter 2022 Financial Results on November
9, 2022

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the
"Company"), today announced that it plans to report its third quarter 2022
financial results after market close on November 9,...

Sep 1, 2022
Liminal BioSciences Announces Listing Transfer to Nasdaq Capital Market

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company")
announced today that it received confirmation from the Listing Qualifications
Department of The Nasdaq Stock Market...

More News

Corporate Presentation

Corporate Presentation - September 2022

Latest Events
Q3 2022 Results Conference Call
Thursday, November 10, 2022
8:30am - 9:30am EST

Liminal will host a conference call and webcast to discuss financial results at
8:30 am (ET) on Thursday November 10, 2022. The telephone numbers to access the
conference call are 888-205-6786 and...

H.C. Wainwright 24th Annual Global Investment Conference - September 12-14, 2022
Wednesday, September 14, 2022
9:30am EDT
Q2 2022 Results Conference Call
Wednesday, August 10, 2022
8:30am - 9:30am EDT
More Events
Investor Resources

Find out more on how Liminal BioSciences (NASDAQ: LMNL) is developing a pipeline
of novel small molecule therapeutics.

 * SHAREHOLDER
   INFORMATION
   Access useful documents for
   investors of Liminal BioSciences.
 * FAQ
   Find answers to frequently asked
   questions.
 * CONTACT US
   Get in touch with the
   Liminal BioSciences team.

© 2022 Liminal BioSciences Inc. All Rights Reserved. | Legal Disclaimer
| Privacy Policy | Cookie Policy | Social Media Guidelines